These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19519389)

  • 1. The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.
    Montaña AM; Batalla C
    Curr Med Chem; 2009; 16(18):2235-60. PubMed ID: 19519389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fresh platinum complexes with promising antitumor activity.
    Wang X
    Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-based drugs: past, present and future.
    Dilruba S; Kalayda GV
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1103-24. PubMed ID: 26886018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes.
    Lorenzo J; Delgado A; Montaña ÁM; Mesas JM; Alegre MT; Rodríguez Mdel C; Avilés FX
    Eur J Med Chem; 2014 Aug; 83():374-88. PubMed ID: 24980119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basis for design and development of platinum(IV) anticancer complexes.
    Hall MD; Mellor HR; Callaghan R; Hambley TW
    J Med Chem; 2007 Jul; 50(15):3403-11. PubMed ID: 17602547
    [No Abstract]   [Full Text] [Related]  

  • 6. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D
    Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progress in modern structure of platinum complexes.
    Bai L; Gao C; Liu Q; Yu C; Zhang Z; Cai L; Yang B; Qian Y; Yang J; Liao X
    Eur J Med Chem; 2017 Nov; 140():349-382. PubMed ID: 28985575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New platinum antitumor complexes.
    Kelland LR
    Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-platinum complexes in cancer therapy.
    Coluccia M; Natile G
    Anticancer Agents Med Chem; 2007 Jan; 7(1):111-23. PubMed ID: 17266508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.
    Zhao J; Gou S; Liu F
    Chemistry; 2014 Nov; 20(46):15216-25. PubMed ID: 25256173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action.
    Khoury A; Deo KM; Aldrich-Wright JR
    J Inorg Biochem; 2020 Jun; 207():111070. PubMed ID: 32299045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile.
    Park GY; Wilson JJ; Song Y; Lippard SJ
    Proc Natl Acad Sci U S A; 2012 Jul; 109(30):11987-92. PubMed ID: 22773807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approach to accurately predict bond strength and ligand lability in platinum-based anticancer drugs.
    Ponce-Vargas M; Klein J; Hénon E
    Dalton Trans; 2020 Sep; 49(36):12632-12642. PubMed ID: 32870220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photoactivatable platinum complexes.
    Bednarski PJ; Mackay FS; Sadler PJ
    Anticancer Agents Med Chem; 2007 Jan; 7(1):75-93. PubMed ID: 17266506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment.
    Ott I; Gust R
    Anticancer Agents Med Chem; 2007 Jan; 7(1):95-110. PubMed ID: 17266507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness.
    Hambley TW; Battle AR; Deacon GB; Lawrenz ET; Fallon GD; Gatehouse BM; Webster LK; Rainone S
    J Inorg Biochem; 1999 Oct; 77(1-2):3-12. PubMed ID: 10626347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum-based anticancer agents: innovative design strategies and biological perspectives.
    Ho YP; Au-Yeung SC; To KK
    Med Res Rev; 2003 Sep; 23(5):633-55. PubMed ID: 12789689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monofunctional and higher-valent platinum anticancer agents.
    Johnstone TC; Wilson JJ; Lippard SJ
    Inorg Chem; 2013 Nov; 52(21):12234-49. PubMed ID: 23738524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.